Literature DB >> 20972404

Intracranial orthotopic allografting of medulloblastoma cells in immunocompromised mice.

Xi Huang1, Anuraag Sarangi, Tatiana Ketova, Ying Litingtung, Michael K Cooper, Chin Chiang.   

Abstract

Medulloblastoma is the most common pediatric tumor of the nervous system. A large body of animal studies has focused on cerebellar granule neuron precursors (CGNPs) as the cell-of-origin for medulloblastoma. However, the diverse clinical presentations of medulloblastoma subtypes in human patients (nodular, desmoplastic, classical and large cell/anaplastic), and the fact that medulloblastoma is found in a subset of human patients with no ectopic expression of CGNP marker, suggest that the cellular and molecular origins of medulloblastoma are more complex and far from being completely deciphered. Therefore, it is essential to determine whether there is an alternative medulloblastoma tumor cell-of-origin based on which cell-type specific therapeutic modality can be developed. To this end, intracranial orthotopic allografting of genetically marked tumor cell types followed by subsequent analyses of secondary tumor development in recipients will allow determination of the cellular origin of tumor-initiating cells. Here we describe the experimental protocol for intracranial orthotopic allografting of medulloblastoma cells derived from primary tumor tissue, and this procedure can also be used for transplanting cells from established cell lines.

Entities:  

Mesh:

Year:  2010        PMID: 20972404      PMCID: PMC3185618          DOI: 10.3791/2153

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  5 in total

1.  N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma.

Authors:  Jessica D Kessler; Hiroshi Hasegawa; Sonja N Brun; Brian A Emmenegger; Zeng-Jie Yang; John W Dutton; Fan Wang; Robert J Wechsler-Reya
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

2.  Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells.

Authors:  Zeng-Jie Yang; Tammy Ellis; Shirley L Markant; Tracy-Ann Read; Jessica D Kessler; Melissa Bourboulas; Ulrich Schüller; Robert Machold; Gord Fishell; David H Rowitch; Brandon J Wainwright; Robert J Wechsler-Reya
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

3.  Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1.

Authors:  Ettore Salsano; Laura Croci; Emanuela Maderna; Linda Lupo; Bianca Pollo; Maria Teresa Giordana; G Giacomo Consalez; Gaetano Finocchiaro
Journal:  Neuro Oncol       Date:  2007-05-23       Impact factor: 12.300

4.  Deletion of Atoh1 disrupts Sonic Hedgehog signaling in the developing cerebellum and prevents medulloblastoma.

Authors:  Adriano Flora; Tiemo J Klisch; Gabriele Schuster; Huda Y Zoghbi
Journal:  Science       Date:  2009-12-04       Impact factor: 47.728

5.  Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma.

Authors:  Ulrich Schüller; Vivi M Heine; Junhao Mao; Alvin T Kho; Allison K Dillon; Young-Goo Han; Emmanuelle Huillard; Tao Sun; Azra H Ligon; Ying Qian; Qiufu Ma; Arturo Alvarez-Buylla; Andrew P McMahon; David H Rowitch; Keith L Ligon
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

  5 in total
  2 in total

1.  Investigation of brain tissue infiltration by medulloblastoma cells in an ex vivo model.

Authors:  Anuja Neve; Karthiga Santhana Kumar; Dimitra Tripolitsioti; Michael A Grotzer; Martin Baumgartner
Journal:  Sci Rep       Date:  2017-07-13       Impact factor: 4.379

2.  Validation of Cadherin HAV6 Peptide in the Transient Modulation of the Blood-Brain Barrier for the Treatment of Brain Tumors.

Authors:  Babu V Sajesh; Ngoc H On; Refaat Omar; Samaa Alrushaid; Brian M Kopec; Wei-Guang Wang; Han-Dong Sun; Ryan Lillico; Ted M Lakowski; Teruna J Siahaan; Neal M Davies; Pema-Tenzin Puno; Magimairajan Issai Vanan; Donald W Miller
Journal:  Pharmaceutics       Date:  2019-09-17       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.